During the month of December 2015 AroCell AB (publ) conducted a preferential rights issue. The last day for trading with BTA will take place on January 12th 2016 and the stop day is January 14th 2016. BTA’s will be converted to shares January 18th 2016.
After the preferential rights issue the share capital will be 2 867 450,60 SEK distributed on 28 674 506 shares.
Redeye AB is the financial advisor for the preferential rights issue in collaboration with Corpura AB. Legal advisor is Fredersen Advokatbyrå AB.
For more information:
Jan Stålemark, CEO
AroCell AB (publ)
About AroCell AB (publ)
AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com. AroCell AB (AROC) is listed at AktieTorget and has about 2 300 shareholders.